Pavel ME et al. - In the current study it was shown that health-related quality of life (HRQOL) was preserved for patients with advanced, non-functional, gastrointestinal or lung neuroendocrine tumors (NETs); no differences existed between the everolimus and placebo groups. Moreover, everolimus was shown to delay disease progression while preserving overall HRQOL.

Methods
Adults greater than or equal to 18 years of age with pathologically-confirmed, advanced, non-functional, well-differentiated gastrointestinal or lung NETs were recruited.
Patients received oral everolimus (10 mg per day) or placebo.
HRQOL was assessed with the Functional Assessment of Cancer Therapy—General (FACT-G) questionnaire at baseline (visit 2, day 1), every 8 weeks during the study for the first 12 months after randomisation, and every 12 weeks thereafter until study drug discontinuation. 

Results
302 patients were enrolled.
The median time to definitive deterioration in FACT-G total score was 11.27 months with everolimus and 9.23 months with placebo (aHR = 0·81).